4.7 Article

Signaling function of PRC2 is essential for TCR-driven T cell responses

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 215, Issue 4, Pages 1101-1113

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20170084

Keywords

-

Funding

  1. National Institutes of Health [R01GM112811, R21 AI122093]
  2. GlaxoSmithKline [100026128]
  3. Open Philanthropy Project/Good Ventures Foundation
  4. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI122093] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM112811] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Differentiation and activation of T cells require the activity of numerous histone lysine methyltransferases (HMT) that control the transcriptional T cell output. One of the most potent regulators of T cell differentiation is the HMT Ezh2. Ezh2 is a key enzymatic component of polycomb repressive complex 2 (PRC2), which silences gene expression by histone H3 di/tri-methylation at lysine 27. Surprisingly, in many cell types, including T cells, Ezh2 is localized in both the nucleus and the cytosol. Here we show the presence of a nuclear-like PRC2 complex in T cell cytosol and demonstrate a role of cytosolic PRC2 in T cell antigen receptor (TCR)-mediated signaling. We show that short-term suppression of PRC2 precludes TCR-driven T cell activation in vitro. We also demonstrate that pharmacological inhibition of PRC2 in vivo greatly attenuates the severe T cell-driven autoimmunity caused by regulatory T cell depletion. Our data reveal cytoplasmic PRC2 is one of the most potent regulators of T cell activation and point toward the therapeutic potential of PRC2 inhibitors for the treatment of T cell-driven autoimmune diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Immunology

Lipid-Reactive T Cells in Immunological Disorders of the Lung

Seungwon Ryu, Joon Seok Park, Hye Young Kim, Ji Hyung Kim

FRONTIERS IN IMMUNOLOGY (2018)

Article Biochemistry & Molecular Biology

Role of non-classical T cells in skin immunity

Joon Seok Park, Ji Hyung Kim

MOLECULAR IMMUNOLOGY (2018)

Article Biochemistry & Molecular Biology

The catalytic domain of the histone methyltransferase NSD2/MMSET is required for the generation of B1 cells in mice

Marc-Werner Dobenecker, Jonas Marcello, Annette Becker, Eugene Rudensky, Natarajan Bhanu, Thomas Carrol, Benjamin A. Garcia, Rabinder Prinjha, Vyacheslav Yurchenko, Alexander Tarakhovsky

FEBS LETTERS (2020)

Article Biochemistry & Molecular Biology

The Selenoprotein MsrB1 Instructs Dendritic Cells to Induce T-Helper 1 Immune Responses

Ho-Jae Lee, Joon Seok Park, Hyun Jung Yoo, Hae Min Lee, Byung Cheon Lee, Ji Hyung Kim

ANTIOXIDANTS (2020)

Article Multidisciplinary Sciences

Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention

Ian J. Groves, Sarah E. Jackson, Emma L. Poole, Aharon Nachshon, Batsheva Rozman, Michal Schwartz, Rab K. Prinjha, David F. Tough, John H. Sinclair, Mark R. Wills

Summary: HCMV reactivation from latency poses a significant health risk for transplant recipients. Epigenetic inhibitors, particularly histone deacetylase inhibitors and bromodomain inhibitors, have been found effective in inducing virus immediate early gene expression, providing a potential strategy for reducing HCMV-related morbidity and mortality.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Oncology

Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses

Chun-Shan Liu, Inmaculada Rioja, Ali Bakr, Marlon R. Veldwijk, Elena Sperk, Carsten Herskind, Dieter Weichenhan, Rab K. Prinjha, Christoph Plass, Peter Schmezer, Odilia Popanda

Summary: This study investigated the effects and toxicity of different inhibitors targeting BET proteins on radiation-induced fibroblast activation. The results showed that BD2-selective targeting inhibitors efficiently suppressed the expression of DGKA and profibrotic markers without showing cytotoxicity.

INTERNATIONAL JOURNAL OF CANCER (2022)

Article Multidisciplinary Sciences

Bromodomain factor 5 is an essential regulator of transcription in Leishmania

Nathaniel G. Jones, Vincent Geoghegan, Gareth Moore, Juliana B. T. Carnielli, Katherine Newling, Felix Calderon, Raquel Gabarro, Julio Martin, Rab K. Prinjha, Inmaculada Rioja, Anthony J. Wilkinson, Jeremy C. Mottram

Summary: Leishmania require the bromodomain-enriched CRKT complex for interpreting histone acetylation marks and maintaining normal gene expression and cellular viability.

NATURE COMMUNICATIONS (2022)

Article Biochemistry & Molecular Biology

Uncoupled glycerol-3-phosphate shuttle in kidney cancer reveals that cytosolic GPD is essential to support lipid synthesis

Cong-Hui Yao, Joon Seok Park, Kiran Kurmi, Song-Hua Hu, Giulia Notarangelo, Joseph Crowley, Heidi Jacobson, Sheng Hui, Arlene H. Sharpe, Marcia C. Haigis

Summary: The glycerol-3-phosphate shuttle is uncoupled in kidney cancer cells, with the cytosolic reaction being much faster than the mitochondrial reaction. Knocking down mitochondrial GPD has no effect on mitochondrial respiration, but leads to upregulation of cytosolic GPD and increased glycerol-3-phosphate supply, promoting cancer cell proliferation. Inhibition of lipid synthesis can abolish the proliferative advantage of GPD2 knockdown tumor.

MOLECULAR CELL (2023)

Article Multidisciplinary Sciences

Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance

Joon Seok Park, Francesca S. Gazzaniga, Meng Wu, Amalia K. Luthens, Jacob Gillis, Wen Zheng, Martin W. LaFleur, Sarah B. Johnson, Golnaz Morad, Elizabeth M. Park, Yifan Zhou, Stephanie S. Watowich, Jennifer A. Wargo, Gordon J. Freeman, Dennis L. Kasper, Arlene H. Sharpe

Summary: The gut microbiota plays a vital role in regulating anti-tumor immunity during immune checkpoint inhibitor therapy. Certain bacteria have been found to promote an anti-tumor response to immune checkpoint inhibitors in mice, and transplanting fecal samples from responders can improve the efficacy of anti-PD-1 therapy in melanoma patients. However, the effectiveness of fecal transplants varies, and the mechanisms by which gut bacteria promote anti-tumor immunity are still unclear.

NATURE (2023)

Correction Multidisciplinary Sciences

Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance (vol 617, pg 377, 2023)

Joon Seok Park, Francesca S. Gazzaniga, Meng Wu, Amalia K. Luthens, Jacob Gillis, Wen Zheng, Martin W. LaFleur, Sarah B. Johnson, Golnaz Morad, Elizabeth M. Park, Yifan Zhou, Stephanie S. Watowich, Jennifer A. Wargo, Gordon J. Freeman, Dennis L. Kasper, Arlene H. Sharpe

NATURE (2023)

Review Immunology

Drawing on disorder: How viruses use histone mimicry to their advantage

Alexander Tarakhovsky, Rab K. Prinjha

JOURNAL OF EXPERIMENTAL MEDICINE (2018)

No Data Available